Jo Taylor, Founder of After Breast Cancer Diagnosis, posted the following on X:
“We need drug developments to get through the broken National Institute for Health and Care Excellence severity modifier system & available on NHS England because now we have an inequality in the UK where Scotland can access Enhertu for HER2low but England, Wales & Northern Ireland can’t…
Its a crazy situ that patients are in.
Shame on those who stopped this from being approved… I can only see that this will cause big problems for pharma in the future & we METUPUK worry for what will happen…
Awareness & mammograms wont help us – whats the point of a new drug if its not there to help patients survive? Where are the outcomes?”